Scientists have discovered a potential breakthrough in the fight against obesity: a method to reprogram the pancreas to produce GLP-1 naturally, without the need for injections like Ozempic. This groundbreaking research could revolutionize weight loss and management, offering a more sustainable and potentially safer alternative to current treatments.
GLP-1, a naturally occurring hormone, has been replicated in drugs like semaglutide and tirzepatide, which are highly effective in weight loss. However, these drugs require weekly injections, which can be inconvenient and costly. The new approach aims to stimulate the body's natural production of GLP-1, eliminating the need for ongoing injections.
Two biotech startups are leading the charge. They've developed gene therapy treatments that, in the best-case scenario, would require a single injection to reprogram the body's cells. This therapy would coax existing cells into producing GLP-1, providing the benefits of the hormone without the need for continuous treatment.
Initial tests on mice have shown promising results, with the approach already proven effective. The companies are now testing it on larger animals, including pigs and monkeys, to assess its safety and efficacy in humans. While it's too early to determine if the human body will respond similarly, the potential is exciting.
The use of GLP-1 injectables has doubled in the United States in the last year, according to Gallup data, and obesity rates have started to decline since 2022. Experts suspect that GLP-1 drugs have contributed to this trend. The benefits go beyond weight loss; these drugs also help control blood sugar, lower blood pressure, reduce the risk of heart disease, and improve kidney health.
One of the key players in this field is Fractyl Health, which has developed a gene therapy called Rejuva. In a recent study, obese mice treated with Rejuva lost approximately 20% of their body weight within three weeks. Even normal-weight mice maintained healthy blood sugar levels after being treated and given a high-fat diet.
Fractyl's approach involves using a small virus to insert DNA instructions for GLP-1 production into cells. This method is designed to be safe due to the low dose of the virus required. However, experts caution that this approach in humans could be irreversible and may lead to long-term issues in the pancreas, which is crucial for blood sugar control.
Fractyl's competitor, RenBio, takes a different approach. They include the DNA instructions for GLP-1 production in a saline solution, which is then injected into muscle tissue. Short electrical pulses are used to deliver the instructions directly into cells, effectively turning the cells into protein factories.
Mice injected with this solution lost around 15% of their body weight and maintained this weight loss for at least a year. Blood sugar level regulation also improved. While Fractyl's co-founder, Harith Rajagopalan, is optimistic about seeing human data in the next year, he acknowledges the long road ahead for potential human treatment.
Despite the challenges, the potential of this research is significant. It could offer a more sustainable and potentially safer way to manage weight and related health issues, providing a much-needed alternative to current treatments.
